SageView Advisory Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$1.56M Buy
62,717
+3,820
+6% +$96.3K 0.05% 195
2025
Q3
$1.5M Buy
58,897
+8,023
+16% +$198K 0.05% 205
2025
Q2
$1.24M Sell
50,874
-6,508
-11% -$152K 0.05% 214
2025
Q1
$1.45M Buy
57,382
+10,140
+21% +$265K 0.06% 167
2024
Q4
$1.25M Buy
47,242
+17,241
+57% +$468K 0.05% 190
2024
Q3
$868K Sell
30,001
-19,315
-39% -$563K 0.04% 219
2024
Q2
$1.38M Buy
+49,316
New +$1.36M 0.06% 176
2024
Q1
Sell
-45,186
Closed -$1.22M 718
2023
Q4
$1.22M Buy
45,186
+973
+2% +$29.4K 0.05% 218
2023
Q3
$1.47M Buy
44,213
+14,539
+49% +$514K 0.08% 150
2023
Q2
$1.09M Buy
29,674
+2,345
+9% +$91.3K 0.06% 209
2023
Q1
$1.12M Buy
27,329
+13,268
+94% +$573K 0.07% 188
2022
Q4
$720K Buy
+14,061
New +$674K 0.06% 196

Other funds holding PFE

SageView Advisory Group's PFE Position: Q4 2025 in Review

SageView Advisory Group increased its Pfizer (PFE) stake by 6.5% in Q4 2025, buying an estimated $96.3K and bringing the position to 62,717 shares worth $1.56M. The position accounts for 0.05% of the portfolio, ranked #195.

SageView Advisory Group first reported a position in PFE in Q4 2022 and has held it in 12 quarters since. 2,906 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • SageView Advisory Group held 62,717 shares of Pfizer worth $1.56M as of Q4 2025.
  • SageView Advisory Group bought 3,820 Pfizer shares in Q4 2025, an estimated $96.3K.
  • Pfizer made up 0.05% of SageView Advisory Group's portfolio in Q4 2025, its #195 holding.
  • SageView Advisory Group first reported a position in Pfizer in Q4 2022 and has held it in 12 quarters since.
  • 2,906 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.